In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 4.71 below Caribou Biosciences Inc average.

Within Biotechnology & Pharmaceuticals industry 55 other companies have achieved higher Quick Ratio than Caribou Biosciences Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 573 to 602.

Explain Quick Ratio?
How much Cash & cash equivalents CRBU�s has?
What are CRBU�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CRBU/financial-strength

https://api.csimarket.com/api/v1/companies/CRBU/fundamentals

https://api.csimarket.com/api/v1/companies/CRBU/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

CRBU Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-28.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-35.57 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	4.71	Subscribe	Subscribe	Subscribe	Subscribe
CRBU's Total Ranking	# 602	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	12.07 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-16.62 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 56
Healthcare Sector	# 258
Overall Market	# 602

Quick Ratio Statistics
High	Average	Low
16.64	8.76	1.2
(Sep 30 2021)		(Dec 31 2020)

Financial Statements
Caribou Biosciences Inc 's Current Liabilities	$ 20 Millions	Visit CRBU's Balance sheet
Caribou Biosciences Inc 's Cash & cash equivalent	$ 95 Millions	Visit CRBU's Balance sheet
Source of CRBU's Sales		Visit CRBU's Sales by Geography

Cumulative Caribou Biosciences Inc 's Quick Ratio

CRBU's Quick Ratio for the trailling 12 Months

CRBU Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-28.33 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-37.85 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	5.6	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3613	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-8.69 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-10.11 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to CRBU Financial Strength Comparisons >> Go to Compare CRBU Quick Ratio to its Competitors

News about Caribou Biosciences Inc Quick Ratio

Evaluating Caribou Biosciences Insights From Financial Analysts

Caribou Biosciences Inc., a biopharmaceutical company focused on CRISPR genome-editing technology, has recently garnered attention from financial analysts. This article aims to provide a comprehensive analysis of Caribou Biosciences based on insights from notable financial analysts and recent developments.Financial Analysts 12-Month Price Targets:According to a report published on July 17, 2024, financial analysts have revealed their 12-month price targets for Caribou Biosciences. The average target stands at $15.25, with a high estimate of $24.00 and a low estimate of $9.00. This current average suggests a potential increase of 19.74%. These price targets indicate a positive sentiment among analysts regarding the future prospects of Caribou Biosciences.

On the trailing twelve months basis In spite of the year on year decrease in CRBU's Current Liabilities to $20.14 millions, cumulative Quick Ratio to 5.6 below the CRBU average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Caribou Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3586 to 3613.

Explain Quick Ratio?
How much Cash & cash equivalents CRBU�s has?
What are CRBU�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 140
Healthcare Sector	# 861
Within the Market	# 3613

trailing twelve months Quick Ratio Statistics
High	Average	Low
14	9.03	5.32
(Jun 30 2022)		(Sep 30 2021)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Beam Therapeutics Inc	12.72	$ 1,043.873 Millions	$ 82.076 Millions
X4 Pharmaceuticals Inc	12.53	$ 187.701 Millions	$ 14.984 Millions
Odyssey Therapeutics, Inc.	12.49	$ 326.001 Millions	$ 26.101 Millions
Solid Biosciences Inc	11.46	$ 348.928 Millions	$ 30.454 Millions
Kalaris Therapeutics Inc	9.73	$ 82.856 Millions	$ 8.514 Millions
Zura Bio Limited	9.22	$ 187.652 Millions	$ 20.349 Millions
Scribe Therapeutics, Inc.	9.19	$ 348.383 Millions	$ 37.928 Millions
Protara Therapeutics Inc	8.83	$ 127.050 Millions	$ 14.391 Millions
Candel Therapeutics Inc	7.42	$ 203.116 Millions	$ 27.388 Millions
4d Molecular Therapeutics Inc	7.16	$ 375.033 Millions	$ 52.394 Millions
Immunovant Inc	6.94	$ 722.274 Millions	$ 104.022 Millions
Repligen Corp	6.87	$ 862.979 Millions	$ 125.686 Millions
Kyverna Therapeutics Inc	6.79	$ 170.572 Millions	$ 25.136 Millions
Compass Therapeutics Inc	6.69	$ 163.058 Millions	$ 24.368 Millions
Black Diamond Therapeutics Inc	6.62	$ 102.030 Millions	$ 15.405 Millions
Krystal Biotech Inc	6.45	$ 916.484 Millions	$ 142.144 Millions
Voyager Therapeutics Inc	6.35	$ 106.806 Millions	$ 16.813 Millions
Cabaletta Bio Inc	6.33	$ 299.383 Millions	$ 47.332 Millions
Cognition Therapeutics inc	6.00	$ 30.758 Millions	$ 5.128 Millions
Replimune Group Inc	5.57	$ 307.833 Millions	$ 55.271 Millions
Denali Therapeutics Inc	5.42	$ 516.196 Millions	$ 95.258 Millions
In8bio Inc	5.32	$ 13.973 Millions	$ 2.628 Millions
Scholar Rock Holding Corp	5.16	$ 413.599 Millions	$ 80.124 Millions
Revolution Medicines Inc	4.81	$ 3,651.385 Millions	$ 758.773 Millions
Prokidney Corp	4.72	$ 141.864 Millions	$ 30.038 Millions
Caribou Biosciences Inc	4.71	$ 94.881 Millions	$ 20.144 Millions
Recursion Pharmaceuticals Inc	4.47	$ 549.853 Millions	$ 122.918 Millions
Lineage Cell Therapeutics Inc	4.42	$ 45.199 Millions	$ 10.217 Millions
Ginkgo Bioworks Holdings Inc	4.33	$ 285.361 Millions	$ 65.849 Millions
Fate Therapeutics Inc	4.26	$ 139.132 Millions	$ 32.691 Millions

Date modified: 2026-11-06T08:41:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.